Comment by kvejdani

Darmiyan's product is NOT a probabilistic risk assessment test, and is NOT intended for use by the general public. There are already too many tests in the market for risk assessment, which are just probability numbers. Darmiyan's product is a software for quantitative assessment of micro-structural abnormality (neurodegeneration) in every voxel of brain MRI. You can think of it as a quantitative virtual microscope. Our maps and reports are not intended for use by the general public. Once we receive FDA approval in about a year or so, the Darmiyan test (software analysis of brain MRI) has to be ordered by a physician and interpreted by a physician to assist in clinical diagnosis and intervention recommendations, if any. The guidelines on Darmiyan test indications and interpretations will be determined by the medical community.